Invivyd (NASDAQ:IVVD) Stock Rating Upgraded by EF Hutton Acquisition Co. I

Invivyd (NASDAQ:IVVD) was upgraded by investment analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a report issued on Wednesday, Zacks.com reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Invivyd in a research note on Tuesday.

Invivyd Stock Performance

NASDAQ:IVVD opened at $0.89 on Wednesday. Invivyd has a 12-month low of $0.81 and a 12-month high of $5.20. The company’s 50-day moving average is $0.99 and its two-hundred day moving average is $1.40.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.03). The business had revenue of $2.26 million during the quarter, compared to the consensus estimate of $4.91 million. Analysts forecast that Invivyd will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of Invivyd

A number of institutional investors and hedge funds have recently bought and sold shares of IVVD. Chase Investment Counsel Corp acquired a new position in shares of Invivyd during the 1st quarter valued at $271,000. SG Americas Securities LLC acquired a new position in Invivyd during the 1st quarter worth approximately $56,000. Vanguard Group Inc. raised its stake in shares of Invivyd by 3.9% during the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock valued at $11,594,000 after purchasing an additional 97,496 shares during the period. Acadian Asset Management LLC purchased a new position in Invivyd in the 1st quarter valued at about $905,000. Finally, Jacobs Levy Equity Management Inc. grew its stake in Invivyd by 21.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock valued at $1,933,000 after purchasing an additional 77,603 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.